Michael T Schweizer, Roman Gulati, Todd Yezefski, Heather H Cheng, Elahe Mostaghel, Michael C Haffner, Radhika A Patel, Navonil De Sarkar, Gavin Ha, Ruth Dumpit, Brianna Woo, Aaron Lin, Patrick Panlasigui, Nerina McDonald, Michael Lai, Katie Nega, Jeannette Hammond, Petros Grivas, Andrew Hsieh, Bruce Montgomery, Peter S Nelson, Evan Y Yu
BACKGROUND: Bipolar androgen therapy (BAT) results in rapid fluctuation of testosterone (T) between near-castrate and supraphysiological levels and has shown promise in metastatic castration-resistant prostate cancer (mCRPC). Its clinical effects may be mediated through induction of DNA damage, and preclinical studies suggest synergy with PARP inhibitors. PATIENTS AND METHODS: This was a single-center, Phase II trial testing olaparib plus BAT (T cypionate/enanthate 400 mg every 28 days) with ongoing androgen deprivation...
December 23, 2022: Prostate Cancer and Prostatic Diseases